SciSparc Ltd. SPRC announced on Tuesday that the European Patent Office has granted it a new patent.
The European Application No. 16786064.2 - titled Combinations of Cannabinoids and N-Acylethanolamines - aligns with the company's objective to increase the safety of cannabinoid treatments while maintaining their therapeutic effects.
The Israel-based company was granted the patent in the United States, Japan and Australia.
The patent relates to compositions and methods for potentiating therapeutic effects and/or reducing side effects of selected cannabinoids of the cannabis plant. It also provides pharmaceutical compositions comprising cannabinoids and N-acyl ethanolamines and methods for their use in various indications amenable to treatment with cannabinoids.
"SciSparc's assets continue to expand, both intellectual property alongside revenue generating assets," said Oz Adler, SciSparc's CEO. "The company continues to lead in this space with a robust IP portfolio worldwide. We continue to believe that cannabinoid-based medicines have enormous therapeutic potential and therefore, we continue to strengthen the patent protection around the technologies we develop".
SPRC Price Action
SciSparc's shares traded 37.06% higher at $5.04 per share at the time of writing on Tuesday morning.
Related News
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.